Psychedelic medicine has regained momentum in 2025. Investors are coming back, regulatory attitudes are softening, trial results are improving and major pharmaceutical firms that kept their distance are starting to pay attention.

This is quite a turnaround for a sector whose share prices collapsed and whose funding dried up...